Bayer Co.Lab Catalyst Award Event
Join us for an exclusive opportunity to witness five groundbreaking startups—led by Nucleate alumni—pitch for the prestigious Bayer Co.Lab Catalyst Lab Space Award, a game-changing prize worth $100K in LabCentral BioBucks! 💰🏆 Hosted in partnership with LabCentral, a premier launchpad for early-stage biotech companies, this live pitch showcase will feature five semi-finalists selected from the Nucleate alumni network.
These ventures, chosen for their scientific excellence and translational potential, will compete for the top prize in front of a panel of industry-leading judges. Beyond the competition, this is your chance to connect with top biotech leaders from Nucleate and Bayer, explore cutting-edge innovations, and network with the scientists, founders, and investors shaping the future of life sciences. Who will walk away with the grand prize? Be there to find out!
⏰ Agenda
5:00 - 5:30 PM | Registration & Check-in
5:30 - 5:45 PM | Opening Remarks
5:45 - 6:45 PM | Pitch Competition
5 companies present
Each company: 5 min pitch + 5 min Q&A
6:45 - 7:00 PM | Closing Remarks
7:00 - 7:15 PM | Announcement of Winner
Present the Bayer Co.Lab Catalyst Lab Space Award ($100K in LabCentral BioBucks)
7:15 - 8:00 PM | Networking
Open networking session with Nucleate, Bayer, LabCentral, and industry leaders
About the Semi Finalists:
Lamprna Therapeutics: Lamprna is revolutionizing RNA-targeting therapeutics with a novel receptor-mediated degradation platform, achieving robust and precise RNA knockdown.
Voyant: Our spatial biology platform generates new therapeutics that overcome immunotherapy resistance by targeting immune cell interactions.
Procure Bio: A novel, non-viral protein nanoparticle platform enabling cell-targeted delivery of nucleic acid and protein therapies.
Cloverleaf Bio: Cloverleaf Bio is developing a new platform of engineered tRNA therapeutics to improve patient outcomes in oncology.
Nephrogen: Curative gene therapies for kidney diseases using adeno-associated viruses and CRISPR-Cas genome editing.
Judging Panel:
Fiona Mack, VP, Head of Bayer Co.Lab Cambridge, US
Nathan Young, Director of Oncology Research, Bayer
Carla Klattenhoff, Sr. Director, Scientific US Lead for Research and Early Development in CV, Renal & Immunology
Johannes Fruehauf: Founder & CEO, LabCentral, BioLabs
About Nucleate:
Nucleate is a 501(c)(3) nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 41 geographic regions and participation from over 280 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies. Visit www.nucleate.xyz for more information, and visit https://nucleate.xyz/privacy-policy/ to read our privacy policy.
About Bayer:
Bayer is a global enterprise with core competencies in the life science fields of healthcare and agriculture committed to advancing innovation and supporting the next generation of biotech ventures. Their Co.Lab initiative is a growing global network of life science incubators that provides entrepreneurs and early-stage companies access to state-of-the-art facilities, resources, and expertise with no strings attached. The Bayer Co.Lab takes a high-touch, tailored approach to support resident companies, and residents have the opportunity to engage, exchange, and share their experience and ideas across international Bayer Co.Lab locations.